BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating ...

A Brukinsa regimen has delivered a large progression-free survival (PFS) benefit in what BeOne Medicines called a “new ...

BeOne Medicines reports positive results from phase 3 MANGROVE study of Brukinsa in frontline mantle cell lymphoma: San Carlos, California Thursday, July 2, 2026, 10:00 Hrs [IST] ...

Patients with newly diagnosed mantle cell lymphoma (MCL) could avoid chemotherapy with a regimen based on BeOne Medicines' ...

Data from EULAR 2026 show that next-generation CAR T- and NK cell platforms induce powerful, drug-free clinical remissions in patients with highly refractory rheumatic diseases.

Kris shared a health update, revealing that she has been dealing with post-COVID fatigue syndrome, lupus flare-ups, and ...

Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma (DLBLC), a positive phase 3 combination ...

Kris Aquino shared a funny and affectionate moment with Ryzza Mae in a throwback Eat Bulaga clip, where the two exchanged ...

BeOne Medicines Ltd. ONC shares are trading lower on Tuesday as the company shared topline results from its Phase 3 MANGROVE ...

Ever Supreme Bio Technology Co., Ltd. (TWSE: 6712) announced on June 28 that CAR001, its proprietarily developed, allogeneic, ...

Tavneos (avacopan) is a brand-name prescription drug that’s used to treat certain types of vasculitis (blood vessel inflammation) in adults. The typical Tavneos dosage is 30 mg (three 10-mg capsules) ...

Detailed price information for Kyverna Therapeutics Inc (KYTX-Q) from The Globe and Mail including charting and trades.